Caladrius Biosciences Appoints Gregory R. Brown, MD, to its Board of Directors
12 October 2016 - 10:30PM
Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the
“Company”), a cell therapy company combining an industry-leading
development and manufacturing services provider (PCT) with a
unique, promising therapeutic development pipeline, announces today
the appointment of Gregory R. Brown, MD, to its Board of Directors.
Dr. Brown will serve as Chairman of the Audit Committee and a
member of the Nominating and Governance Committee of the Company.
Dr. Brown is a co-founder and Vice Chairman of HealthCare
Royalty Partners (HCR Partners), a healthcare-focused private asset
management firm investing in biopharmaceutical and medical
products, and developing and deploying innovative, risk-mitigated
investment strategies to deliver non-correlated cash flow.
Dr. Brown was educated as a transplantation immunologist and
trained as a thoracic and vascular surgeon. He practiced thoracic
and vascular surgery in a community setting where he also founded
and led an HMO. He brings particular expertise in the scientific,
technical, clinical and medical evaluation of products as well as
in healthcare systems and payor/reimbursement dynamics. He has been
involved in sourcing, performing due diligence on and closing more
than $1 billion of royalty financings.
Before co-founding HCR Partners, Dr. Brown was a partner at Paul
Capital Partners, where he co-managed that firm's royalty
investments as a member of the royalty management committee. Prior
to beginning his principal investment career in 2003, Dr. Brown was
co-head of investment banking and head of healthcare at Adams,
Harkness & Hill (now Canaccord Genuity) and a ranked
biotechnology research analyst at Vector Securities International.
Dr. Brown holds a BA from Yale, an MD from SUNY Upstate Medical
Center and an MBA from Harvard Business School. He currently serves
on the boards of MonoSol Rx and Vanderbilt Clinical S.a.r.l.
“We are delighted to welcome Dr. Brown to the Caladrius Board
and are confident that his investment and biopharmaceutical
industry experience will be of great value. His background
and expertise are timely additions that we expect will augment the
breadth and depth of our strategy at this formative time in our
Company’s evolution,” said David J. Mazzo, PhD, Chief Executive
Officer of Caladrius.
“My experience in this industry has provided me with the ability
to recognize the potential of promising companies and technologies,
both from an investment and a medical perspective. I am pleased to
join the Caladrius Board and look forward to being a part of the
Company’s future,” said Dr. Brown.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is advancing a proprietary platform
technology for immunomodulation by pioneering the use of T
regulatory cells as an innovative therapy for recent onset type 1
diabetes. The product candidate, CLBS03, is the subject of an
ongoing Phase 2 clinical trial (The Sanford Project: T-Rex study)
in collaboration with Sanford Research, and has been granted Orphan
Drug and Fast Track designation by the U.S. Food and Drug
Administration and Advanced Therapeutic Medicinal Product
classification by the European Medicines Agency. The
Company’s PCT subsidiary is a leading development and manufacturing
partner to the cell therapy industry. PCT works with its
clients to overcome the fundamental challenges of cell therapy
manufacturing by providing a wide range of innovative services
including product and process development, GMP manufacturing,
engineering and automation, cell and tissue processing, logistics,
storage and distribution, as well as expert consulting and
regulatory support. PCT and Hitachi Chemical Co., Ltd. have
entered into a strategic global collaboration to accelerate the
creation of a global commercial cell therapy development and
manufacturing enterprise with deep engineering expertise. For
more information, visit www.caladrius.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements reflect management’s current
expectations, as of the date of this press release, and involve
certain risks and uncertainties. All statements other than
statements of historical fact contained in this press release are
forward-looking statements. The Company’s actual results could
differ materially from those anticipated in these forward-looking
statements as a result of various factors. Factors that could cause
future results to materially differ from the recent results or
those projected in forward-looking statements include the “Risk
Factors” described in the Company’s Annual Report on Form 10-K
filed with the Securities and Exchange Commission (“SEC”) on March
15, 2016, and in the Company’s other periodic filings with the SEC.
The Company’s further development is highly dependent on, among
other things, future medical and research developments and market
acceptance, which are outside of its control.
Contacts:
Investors:
LHA
Anne Marie Fields
Senior Vice President
Phone: +1-212-838-3777
Email: afields@lhai.com
Media:
Caladrius Biosciences, Inc.
Eric Powers
Director, Communications and Marketing
Phone: +1-212-584-4173
Email: epowers@caladrius.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Apr 2024 to May 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From May 2023 to May 2024